SynthesisGenome medicine2026
Cross-ancestry genome-wide association studies of liver function biomarkers uncover pleiotropic variants, systemic disease links and therapeutic targets.
Synthesis in Genome medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundLiver function-related quantitative biomarkers (LFQBs) are essential for assessing hepatic health, yet prior genome-wide association studies (GWAS) have largely studied them in isolation. We conducted cross-ancestry GWAS meta-analyses on seven LFQBs to further elucidate liver function’s genetic architecture, identify pleiotropic variants, and prioritize genes to pinpoint targets with therapeutic potential.
methodsWe performed GWAS meta-analyses on seven LFQBs in ~ 456,000 individuals across East Asian, European, South Asian, and African ancestries, followed by a series of downstream analyses, including fine-mapping, phenome-wide association study (PheWAS), gene-linking, and Mendelian randomization (MR).
resultsWe identified 5,507 lead signals (P < 5 × 10−9), including 210 novel ones. Fine-mapping revealed 2,012 putative causal variants, of which 38 concurrently exhibited causal signals across multiple LFQBs and showed widespread associations with liver- and metabolism-related traits in PheWAS. Additionally, polygenic risk score (PRS)-based PheWAS uncovered pan-systemic manifestations of hepatic homeostasis disruption across diverse phenotypic domains. We proposed a novel multidimensional gene-linking framework (mdS2G) to bridge the identified causal loci to 1,166 putative genes. Benchmarking analysis revealed that mdS2G exhibited superior hepatocyte enrichment compared to individual constituent strategies. Furthermore, MR analysis highlighted PEPD protein as exhibiting therapeutic potential for metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis (P = 2.24 × 10−5, 4.36 × 10−3, respectively).
conclusionsThis study maps the genetic landscape of liver function with expanded ancestral diversity, uncovering key variants and genes tied to hepatic homeostasis disruption and laying the groundwork for targeted liver disease therapies. Additionally, our open-access gene-linking framework provides a resource for the rapid prioritization of putative genes to guide future experimental interrogation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.